Search Bar & Filters
Found 5 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying the use of albumin combined with endovascular treatment in patients who have an acute ischemic stroke in the anterior circulation. This trial is a prospective, multicenter, open-label, randomized controlled study aiming to determine the safety and effectiveness of adding albumin to the standard endovascular therapy for this condition. Patients will be selected based on specific criteria including stroke severity and imaging findings. Participants will be randomly assigned to one of two groups one receiving albumin along with endovascular treatment, and the other receiving only the recommended endovascular treatment. Albumin is given as a 25% human albumin intravenous infusion at a dose of 0.5gkg maximum 37.5g once initially and then daily for the next three days. Both groups will also receive acute stroke care and secondary prevention therapies according to current guidelines. During the study, participants will undergo initial imaging tests such as CT or MRI scans to confirm stroke location and exclude hemorrhage, along with laboratory tests and stroke severity assessments including the NIH Stroke Scale and modified Rankin Scale. Vital signs will be monitored, and patients will be followed for 90 days after randomization via telephone to evaluate their recovery and quality of life. The primary outcome is the proportion of patients achieving good functional status or returning to their baseline by 90 days.
Actively Recruiting
Stroke is one of the leading causes of death worldwide, with ischemic stroke being the most common type. Researchers are evaluating whether early administration of oral aspirin after intravenous thrombolysis improves functional outcomes for patients with acute ischemic stroke. The study aims to determine if starting aspirin treatment within 3 hours of thrombolysis can prevent neurological deterioration without increasing bleeding risks. Participants are randomly assigned to one of two groups the interventional group receives 300 mg of oral aspirin shortly after starting intravenous thrombolysis, while the control group receives a placebo. Both groups receive the best standard medical care according to current guidelines. Aspirin tablets may be chewed or given via a nasogastric tube if swallowing is difficult. The treatment is administered within 3 hours of initiating thrombolysis. During the study, participants are monitored for neurological improvements and potential complications using scales like the modified Rankin scale and NIH Stroke Scale at various time points up to 90 days after stroke. Researchers will assess functional outcomes, neurological changes, and safety measures, including the risk of intracranial hemorrhage. The total follow-up period extends to 90 days post-stroke.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of combining an interleukin-6 inhibitor called tocilizumab with endovascular therapy in adults who have experienced an acute posterior circulation large-vessel occlusion stroke. This phase III clinical trial aims to see if adding tocilizumab can improve recovery outcomes for these patients. The trial is randomized, double-blind, and placebo-controlled, ensuring a rigorous comparison between treatments. Participants will receive either endovascular treatment combined with a single intravenous infusion of 240 mg tocilizumab or endovascular treatment combined with a placebo infusion. The infusion will be given immediately after randomization within 30 minutes and will take more than one hour to complete. This study involves two groups running in parallel to compare the effects of tocilizumab against placebo. During the study, participants will be assessed on their recovery using the modified Rankin Scale at 90 days as the main measure. Additional assessments include neurological improvement shortly after treatment, stroke severity scores at 7 days, and quality of life evaluations up to one year. Safety and functional outcomes will be closely monitored through various scales and indexes, with the total follow-up lasting up to one year after treatment.
Actively Recruiting
Researchers are evaluating Shuxuening injection, a multi-target neuroprotective agent, to see its effects when added to intravenous thrombolysis therapy in patients with acute ischemic stroke. This large, multicenter, randomized, double-blind, placebo-controlled trial aims to assess the effectiveness and safety of Shuxuening injection in improving outcomes after stroke. Intravenous thrombolysis with rt-PA is the current standard treatment, but many patients still experience significant disability, so neuroprotective agents like Shuxuening may help reduce brain cell death. Participants will be randomly assigned to one of two groups one group will receive Shuxuening injection combined with intravenous thrombolysis, and the other will receive a placebo combined with intravenous thrombolysis. Both treatments involve a daily intravenous drip of 20 ml Shuxuening or placebo plus 250 ml of 0.9% sodium chloride for 10 to 14 days. The study plans to enroll 1380 patients within 6 hours of stroke onset from 50 centers across China. During the study, participants will be monitored closely with assessments including the modified Rankin Scale mRS score at 90 days to measure functional recovery, along with safety monitoring for adverse events over 90 days. Other evaluations include neurological function scores, quality of life surveys, and various safety outcomes. The trial will last for at least 90 days after treatment, with data collected on disability, recovery, and any side effects experienced.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of starting direct oral anticoagulants DOACs early versus later in patients who have acute ischemic stroke caused by atrial fibrillation and who develop bleeding complications after emergency endovascular treatment. This multicenter, prospective, open-label, randomized controlled trial aims to determine the best timing to initiate DOAC therapy to balance stroke recurrence and bleeding risks. Participants are assigned to one of two groups one begins any DOAC within 4 weeks after stroke onset early initiation, and the other starts DOACs between 4 and 8 weeks after stroke onset delayed initiation. The trial compares these two timing strategies following emergency endovascular therapy to see which approach is safer and more effective. During the study, participants will be monitored for outcomes including recurrent ischemic stroke, symptomatic brain bleeding, and death over 90 days. Additional assessments include quality of life, functional recovery, vascular events, and bleeding complications up to one year. Researchers will track hospital stay length and use clinical scales such as the modified Rankin Scale and EQ-5D-5L questionnaire to evaluate recovery and health status. The total study duration spans the treatment and follow-up periods up to one year.